美康生物(300439) - 2022 Q1 - 季度财报

Revenue and Profitability - Revenue for Q1 2022 was CNY 577,448,213.25, an increase of 8.70% compared to CNY 531,229,953.71 in the same period last year[2] - Net profit attributable to shareholders decreased by 7.92% to CNY 69,561,237.21 from CNY 75,542,627.24 year-on-year[2] - Net profit excluding non-recurring items fell by 25.83% to CNY 52,824,186.49 compared to CNY 71,224,180.49 in the previous year[2] - The overall gross margin decreased by 5.62 percentage points year-on-year, influenced by the lower gross margins of testing services and agency products compared to self-produced products[14] - Net profit for Q1 2022 was CNY 67,966,450.42, a decrease of 4.1% from CNY 70,936,355.38 in Q1 2021[24] - Earnings per share for Q1 2022 were CNY 0.18, down from CNY 0.21 in the same period last year[25] Cash Flow and Liquidity - The net cash flow from operating activities was negative at CNY -85,484,991.87, a significant decline of 3,865.96% from CNY 2,269,936.86 in the same period last year[2] - The net cash flow from investing activities was CNY 45,049,238.28, a turnaround from CNY -71,539,974.56 in the previous year, mainly due to the redemption of financial products[10] - The total cash inflow from investment activities was 205,311,094.22, a substantial increase from 7,754,460.00 in the prior period, reflecting improved investment recovery[28] - The net cash flow from financing activities was -4,839,993.00, a sharp decline from 404,464,807.35 in the prior period, suggesting challenges in financing[28] - The ending balance of cash and cash equivalents was 629,033,779.45, a decrease from 656,394,969.15 in the previous period, indicating a reduction in liquidity[28] Assets and Liabilities - Total assets at the end of the reporting period were CNY 3,528,193,891.89, down 1.81% from CNY 3,593,187,118.77 at the end of the previous year[2] - Total liabilities decreased to CNY 1,109,550,697.05 from CNY 1,202,449,501.85 at the beginning of the year, reflecting a reduction of approximately 7.7%[20] - Current liabilities decreased to RMB 969.79 million from RMB 1.06 billion at the beginning of the year[19] Shareholders' Equity - Shareholders' equity attributable to the parent company increased by 2.97% to CNY 2,416,708,621.33 from CNY 2,347,016,911.96 at the end of the previous year[2] - The total equity attributable to shareholders increased to CNY 2,416,708,621.33 from CNY 2,347,016,911.96, representing a growth of about 2.9%[20] Expenses and Costs - Total operating costs for Q1 2022 were CNY 507,649,998.55, up 12.4% from CNY 451,921,734.25 in Q1 2021[23] - Research and development expenses for Q1 2022 were CNY 35,417,855.98, an increase of 10.8% compared to CNY 32,059,887.04 in Q1 2021[23] - The cash paid for purchasing goods and services was 420,543,704.42, an increase from 240,155,388.24 in the prior period, indicating higher operational costs[27] - The cash paid to employees was 142,389,280.94, up from 116,043,524.17 in the previous period, reflecting increased payroll expenses[27] - The cash paid for other operating activities was 87,004,125.18, higher than 62,041,963.62 in the previous period, indicating increased operational expenditures[27] Government Support and Investment Income - The company reported a significant increase in government subsidies, which amounted to CNY 13,661,301.97, up 164.64% from CNY 5,162,228.77 in the previous year[9] - Investment income surged by 609.95% to CNY 9,037,301.40 from CNY 1,272,941.37, primarily due to the disposal of subsidiaries[9] Product Development - The company launched 20 new in vitro diagnostic reagent products during the reporting period, including 6 chemiluminescence reagents and 10 mass spectrometry reagents[15] - The company plans to enhance the research and promotion of self-produced products to improve profitability[14] Accounts Receivable and Inventory - Accounts receivable increased to RMB 861.50 million from RMB 810.81 million at the beginning of the year[17] - Inventory rose to RMB 250.50 million, compared to RMB 211.39 million at the start of the year[18]